EXPERIENCE OF THE TREATMENT WITH SEHYDRIN (HYDRAZINE SULFATE, HS)ASTERISK IN THE ADVANCED CANCER-PATIENTS

The results of Sehydrin (Hydrazine Sulfate, HS) treatment of 740 patie nts with the advanced, recurrent or metastatic solid tumours of variou s localizations or malignant lymphomas, for whom all the methods of sp ecific treatment (surgery, radiation, chemotherapy) had been exhausted are presented in this work. The objective response, symptomatic thera peutic effects and toxicity were estimated. Clinically significant obj ective responses were registered in patients with the soft tissue sarc omas, including neuroblastomas, and paradoxically - in such semimalign ant tumours as desmoids. Although the objective response in patients w ith the lung cancer (90% - non-small cell) was only 4%, stabilization of long duration was registered in 22% of cases connected with the imp ressive relief of heavy common symptoms in 38.5% of the treated patien ts. Such a subjective response was established in 46.6% of all the 740 cases. The drug given per os was well tolerated by patients in primar y and subsequent courses and did not induce myelosuppression or other significant side effects. On the basis of observations available, Sehy drin may be assessed as an alternative drug for the treatment and symp tomatic therapy of patients with some advanced solid tumours and malig nant lymphomas at a disease stage when the other methods of treatment can not be used. A possible mechanism of antitumour and symptomatic ac tion is being discussed.